Modified Linear Peptides Effectively Silence STAT-3 in Breast Cancer and Ovarian Cancer Cell Lines (2023)
Sequence: Ac-K-βA-βA-WWWW-βA-βA-RRRR-CONH2
| Experiment Id | EXP000836 |
|---|---|
| Paper | Modified Linear Peptides Effectively Silence STAT-3 in Breast Cancer and Ovarian Cancer Cell Lines |
| Peptide | MLP3 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | no |
| Endosomal Escape Evidence | |
| Peptide Concentration | ≤8.64 µM (max at N/P 40, reported) |
| Rna Concentration | 36 nM (reported for uptake assay; likely similar in functional assays) |
| Mixing Ratio | N/P 20, 40 |
| Formulation Format | peptide/siRNA electrostatic complex (N/P ratio) |
| Formulation Components | MLP peptide + siRNA (saline) |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | MDA-MB-231 |
| Animal Model | |
| Administration Route | |
| Output Type | STAT3 protein downregulation (Western blot) |
| Output Value | No significant STAT3 downregulation |
| Output Units | |
| Output Notes | No significant siRNA uptake by FACS; complex ζ-potential reported as weak (−4.7 to +3.95 mV across N/P 5–40). |
| Toxicity Notes | No significant cytotoxicity up to 10 µM; in peptide/siRNA complexes, max peptide concentration at N/P 40 was 8.64 µM (MTS, 48 h). |
| Curation Notes |